Strategic partnerships Leverage recent collaboration with Terumo ePRISM to position Medis QFR technology as a complementary solution for precision medicine workflows; target cardiovascular centers leveraging Terumo platforms to cross-sell imaging quantification tools.

Global footprint Expand presence with established subsidiaries in the United States, United Kingdom, Canada and Japan to pursue regional deals, channel partnerships and localized support for QAngio XA, QCA-CMS and QMass MR solutions.

Acquisitive growth Capitalize on the AMID acquisition history to approach clinics and labs that value integrated cardiovascular software ecosystems; propose bundled offerings and cross-product integrations to accelerate adoption.

DL imaging lead Highlight ongoing deep learning contour capabilities and future AI-driven quantification as a differentiator for research institutions and large hospitals seeking scalable, automated analysis for left ventricle and other cardiac metrics.

Mid-market focus Position Medis as a mid-market alternative to larger players, emphasizing cost-effective, feature-rich cardiovascular imaging software with a revenue range aligned to mid-sized hospitals and labs; target groups with 51-200 employees and similar peers.